ERCC2 and chronic myelogenous leukemia, BCR-ABL1 positive: XPD 2251A>C polymorphism contributes to hematological neoplasms, such as chronic myeloid leukemia (CML) [32,33], AML [29], and AML transformation [26], and some showed no association [34,35,36].